Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Biotechnology Merger to Spur Development of a Gene Therapy Approach for Treatment of Congestive Heart Failure

By BiotechDaily International staff writers
Posted on 24 Aug 2014
Rapid improvement in the treatment of congestive heart failure (CHF) is expected following the acquisition of InoCard, a German early-stage biotechnology company by uniQure, a Dutch leader in the field of gene therapy.

CHF is characterized by the inability of the cardiac muscle to provide sufficient circulatory support both at rest and during exercise. It is a rapidly progressing disease affecting some 26 million people worldwide, with patients suffering from severe heart failure facing a five-year mortality rate of over 50%.

Currently there is no cure for CHF, but this may change following the purchase of InoCard GmbH (Heidelberg, Germany) by uniQure N.V. (Amsterdam, The Netherlands). InoCard GmbH, a privately held early-stage biotechnology company, has developed an innovative AAV (adeno-associated virus)-based gene therapy approach for the long-term treatment of CHF, targeting the calcium-binding protein S100A1. The Dutch company uniQure has developed a modular platform to rapidly bring new disease-modifying therapies to patients with severe disorders.

The target of the new partnership is to develop a commercially viable gene therapy approach to restore S100A1 levels in CHF patients. Research has shown that administration of S100A1 to CHF patients has beneficial effects on contractile force, growth control of heart muscle cells, and rhythm stability of the heart and is also able to adapt the heart's energy supply to increased cardiac output. In a porcine heart failure model, treatment with InoCard's gene therapy AAV-S100A1 demonstrated a 12-month survival rate of 90%.

"The acquisition of InoCard is a further demonstration of uniQure's strategy to access the best early-stage programs in our industry and accelerate their development by the application of our proven modular platform," said Jörn Aldag, CEO of uniQure. There is strong scientific rationale that addressing calcium dysregulation leads to an astounding effect in congestive heart failure. We believe that together we will deliver the best-in-class treatment for congestive heart failure."

"Despite the continuously growing prevalence of CHF, there have been no therapeutic innovations in decades. InoCard has successfully laid the basis for the development of a long-term, causative treatment of this devastating disease," said Dr. Patrick Most, founder of InoCard. "We believe that combining our promising S100A1 therapy with uniQure's capabilities in innovating safe and effective gene therapies has the potential to transform the treatment of cardiovascular diseases."

Related Links:

uniQure N.V.



Channels

Genomics/Proteomics

view channel
Image: An adult cardiomyocyte has re-entered the cell cycle after expression of miR302-367 (Photo courtesy of the laboratory of Dr. Edward Morrisey, University of Pennsylvania).

Certain MicroRNAs Stimulate Regeneration of Adult Heart Tissue

Cardiac disease researchers working with a mouse model have discovered that by inducing a subset of microRNAs (miRNAs) that are active during development but silenced in the adult they could cause damaged... Read more

Drug Discovery

view channel
Image: Wafers like the one shown here are used to create “organ-on-a-chip” devices to model human tissue (Photo courtesy of Dr. Anurag Mathur, University of California, Berkeley).

Human Heart-on-a-Chip Cultures May Replace Animal Models for Drug Development and Safety Screening

Human heart cells growing in an easily monitored silicon chip culture system may one day replace animal-based model systems for drug development and safety screening. Drug discovery and development... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.